Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: "in explicit technical detail"

...and it would follow that a very successful series of negotiations on the part of TPL / Alliacense would likely result in the use of that explicit technical detail in persuading the J3 to sign on for per product running royalties going forward.

Are you concurring with the above in your read of that SH Letter passage?

Not sure if you are agreeing or disagreeing with the premise.

 

Share
New Message
Please login to post a reply